KYLEE PULSIPHER: Open Payments
NPI 1528609880 · SANDY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,976 in 97 payments from 21 companies in 2025. Trend: 2023 $771 · 2024 $1,998 · 2025 $1,976
Food & beverage: $1,976
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $261 |
| Neurocrine BioSciences, Inc. | 10 | $223 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $143 |
| Alkermes, Inc. | 7 | $141 |
| Vanda Pharmaceuticals Inc. | 5 | $138 |
| Janssen Pharmaceuticals, Inc | 8 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Tris Pharma Inc | 5 | $106 |
| Lundbeck LLC | 5 | $103 |
Products named: VRAYLAR, INGREZZA, REXULTI, CAPLYTA, TRINTELLIX, FANAPT, ARISTADA, Dyanavel XR.
Industry payments across UT — which companies pay providers there.
